AKTi-treated tumor-infiltrating lymphocytes

AKTi-treated tumor-infiltrating lymphocytes (TIL) are autologous immune cells (T cells) isolated from a patient's tumor and expanded ex vivo in the presence of an allosteric inhibitor of the serine/threonine kinase Akt. This pharmacologic intervention during cell culture is designed to enhance the immunologic memory features and persistence of TILs after adoptive transfer. The rationale is that standard expansion protocols often yield terminally differentiated T cells with diminished anti-tumor activity and poor long-term survival. By inhibiting Akt signaling during expansion, these TILs acquire a less-differentiated phenotype associated with improved metabolic fitness, enhanced anti-tumor function, and greater persistence in vivo after infusion into patients. This approach aims to improve the efficacy of adoptive cell therapy for advanced cancers such as metastatic melanoma by augmenting intrinsic qualities of transferred lymphocytes[3].

Other names

Akt inhibitor–treated TILAkti-TILAkt-inhibited TIL